Anti-IRF7 antibody [EPR23509-21] - BSA and Azide free
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(0 Publication)
Rabbit Recombinant Monoclonal IRF7 antibody. Carrier free. Suitable for IP, WB and reacts with Human samples.
View Alternative Names
Interferon regulatory factor 7, IRF-7, IRF7
- IP
Lab
Immunoprecipitation - Anti-IRF7 antibody [EPR23509-21] - BSA and Azide free (AB272225)
IRF7 was immunoprecipitated from 0.35 mg of Jurkat (treated with 100 nM IFN alpha for 18 hours, then added 10 μM MG-132 for another 6 hours) whole cell lysate with ab238137 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab238137 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP)(ab131366), was used as secondary antibody at 1/5000 dilution.
Lane 1 : Jurkat (treated as above) whole cell lysate 10 μg (Input).
Lane 2 : ab238137 IP in Jurkat (treated as above) whole cell lysate.
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab238137 in Jurkat (treated as above) whole cell lysate.
Blocking and dilution buffer and concentration : 5% NFDM/TBST.
Exposure time : 84 seconds.
65-kDa full length IRF7 and 45-kDa C-terminal cleaved IRF7 are observed (PMID : 23175366).
This data was developed using the same antibody clone in a different buffer formulation containing PBS, glycerol, BSA and sodium azide (ab238137).
All lanes:
Immunoprecipitation - Anti-IRF7 antibody [EPR23509-21] (<a href='/en-us/products/primary-antibodies/irf7-antibody-epr23509-21-ab238137'>ab238137</a>)
Predicted band size: 54 kDa
Observed band size: 45 kDa,65 kDa
false
Related conjugates and formulations (1)
-
Anti-IRF7 antibody [EPR23509-21]
Reactivity data
Product details
ab272225 is the carrier-free version of ab238137.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
IRF7 activates and modulates the expression of type I interferons and other cytokines important for antiviral defense. This protein can form part of a larger complex with other IRF family members to enhance its effect on gene transcription. IRF7 operates through its interaction with transcriptional coactivators allowing it to execute its function as a transcriptional activator reinforcing the immune system's response to infectious agents.
Pathways
IRF7 plays a critical role in the Toll-like receptor (TLR) signaling pathway and retinoic acid-inducible gene I (RIG-I) pathway. It directly interacts with MyD88 and IRAK1 proteins linking it to signal transduction pathways that lead to interferon-beta production. The activation of IRF7 in these pathways also strengthens the body's defense mechanism by enhancing the transcription of antiviral genes forming a robust antibacterial and antiviral environment within the host.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com